Details
The purpose of this project is to describe the natural history of coagulopathy among COVID-19 patients. Activities include development of a study synopsis to assess the risks of arterial and venous thromboembolic events, and related death, among COVID-19 patients, assessment of feasibility, and implementation of the study synopsis within select Sentinel Data Partners with electronic health records (EHR) and claims data. The Sentinel Operations Center (SOC) and FDA are partnering with leading infectious disease and hematology specialists from the University of Pennsylvania Perelman School of Medicine on this activity. The workgroup is actively engaging with the Reagan-Udall Foundation (RUF) Evidence Accelerator Parallel Analysis Workgroup.
Additional Information
Contributors
Vincent Lo Re, MD, MSCE; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania
Noelle Cocoros, MPH, DSc; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA
Sarah Dutcher, PhD, MS; Brian Kit, MD, MPH; Silvia Perez-Vilar, PharmD, PhD; Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD
Meighan Rogers Driscoll, MPH; Maria Kempner; Laura Hou; Jenice Ko; John Connolly, PhD; Andrew Petrone, MPH; Jolene Mosely; Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA
Dena Carbonari, MS; Allyson Pishko, MD, MSCE; Sean Hennessy, PharmD, PhD; Perelman School of Medicine, University of Pennsylvania Philadelphia, PA